UTHR — United Therapeutics Share News
0.000.00%
- $25.46bn
- $22.80bn
- $3.18bn
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug
Drugmaker Liquidia rallies on United Therapeutics settlement
Brief: Liquidia Announces Global Settlement Resolving All Pending Litigation With United Therapeutics, Ensuring Continued Commercialization Of Yutrepia In Pah
Brief: United Therapeutics Corporation Prevails In Patent Litigation Against Liquidia
Liquidia slumps after US court rules for United Therapeutics in patent fight
U.S. STOCKS ON THE MOVE-Pyxis Oncology, MongoDB, United Therapeutics
Brief: Liquidia Provides Update On Hatch-Waxman Litigation Tied To ‘327 Patent
United Therapeutics jumps after trial win against Liquidia
Roivant's experimental lung disease drug meets goals in mid-stage study (updated)
Roivant's experimental lung disease drug meets goals in mid-stage study
Brief: United Therapeutics Corporation Announces FDA Filing Acceptance Of New Drug Application For Ralinepag
United Therapeutics Corporation reports results for the quarter ended June 30 - Earnings Summary
United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weakness
Brief: United Therapeutics Appoints Victor Dzau To Board Of Directors On July 22, 2026
Brief: United Therapeutics Acquires Thymmune Therapeutics
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings